The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on the Chinese Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (SHA: 603259). In a press release from BIO CEO John Crowley, the organization announced it is taking steps to dissociate from WuXi AppTec regarding its membership.
In response, WuXi COO for the US and Europe, Richard Connell, stated in a letter that the company will voluntarily withdraw from BIO membership effective immediately, citing “misinformed efforts” that compromise due process. This shift comes amid rising concerns about WuXi AppTec being labeled a potential security risk in recent congressional bills focused on biosecurity, one of which was approved by the US Senate’s homeland security committee last week.
Despite previously defending WuXi AppTec, BIO now emphasizes its commitment to supporting the development of the BIOSECURE Act, which aims to address the risks of over-reliance on China in biotechnology, particularly in manufacturing. The Act includes provisions that could fast-track a ban on US companies collaborating with four specific Chinese firms, including WuXi AppTec, which is the only BIO member among them. BIO’s new position reflects a broader strategy to ensure the US maintains its leadership in biomanufacturing.- Flcube.com
